[68Ga]Ga-FAPI-04 PET/CT在肝脏血管相关间叶源性肿瘤中的表现:与[18F]FDG PET/CT的比较
该研究基于一项前瞻性母研究(ChiCTR2000039099)回顾性分析31例肝脏血管相关间叶源性肿瘤(HVAMT),包括25例肝血管瘤、2例肝上皮样血管内皮瘤和4例肝血管周上皮样细胞肿瘤,所有患者均在一周内完成[68Ga]Ga-FAPI-04 PET/CT与[18F]FDG PET/CT,并比较检出率。结果显示[68Ga]Ga-FAPI-04 PET/CT对HVAMT的检出率高于[18F]FDG PET/CT,但其SUVmax较低而肿瘤/本底比值较高,且SUVmax与病灶最长径呈正相关。
要点
- [68Ga]Ga-FAPI-04 PET/CT对HVAMT总检出率为69.5%(41/59),高于[18F]FDG PET/CT的18.6%(11/59),p < 0.001。
- 肝血管瘤中[68Ga]Ga-FAPI-04 PET/CT的SUVmax中位数为1.30,低于[18F]FDG PET/CT的2.30(p < 0.001),但TBR中位数为1.83,高于后者的1.07(p < 0.001)。
- [68Ga]Ga-FAPI-04 PET/CT的SUVmax与HVAMT病灶最长径呈正相关(r = 0.676,p < 0.001),[18F]FDG PET/CT未见此种相关性。
核心结论
- [68Ga]Ga-FAPI-04 PET/CT在HVAMTs检测中比[18F]FDG PET/CT更敏感。
- 使用[68Ga]Ga-FAPI-04 PET/CT检测其他常见肝脏肿瘤时,也应评估病灶为HVAMT的可能性。
研究设计与样本
- 回顾性分析前瞻性母研究(ChiCTR2000039099)中的31例HVAMT病例,包括25例HH(35个病灶)、2例HEHE(18个病灶)和4例PEComa(6个病灶)。
- 所有患者均在一周内完成[18F]FDG和[68Ga]Ga-FAPI-04 PET/CT检查,比较两种显像的检出率,分析SUVmax、TBR及病灶最长径与SUVmax的相关性,结果经病理和随访验证。
- 母研究注册于中国临床试验注册中心,注册号ChiCTR2000039099,注册日期2020年10月17日。
主要发现
- HH检出率:[18F]FDG PET/CT为2.9%(1/35)vs [68Ga]Ga-FAPI-04 PET/CT为54.3%(19/35),p < 0.001。
- HEHE检出率:[18F]FDG PET/CT为27.8%(5/18)vs [68Ga]Ga-FAPI-04 PET/CT为88.9%(16/18),p = 0.001。
- PEComa检出率:[18F]FDG PET/CT为83.3%(5/6)vs [68Ga]Ga-FAPI-04 PET/CT为100%(6/6)。
- HVAMT总检出率:[18F]FDG PET/CT为18.6%(11/59)vs [68Ga]Ga-FAPI-04 PET/CT为69.5%(41/59),p < 0.001。
- SUVmax中位数:HH中[68Ga]Ga-FAPI-04 PET/CT为1.30 vs [18F]FDG PET/CT为2.30(p < 0.001),HVAMT中为1.60 vs 2.70(p = 0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the efficacy of [68Ga]Ga-FAPI-04 PET/CT in detecting hepatic vascular-associated mesenchymal tumor (HVAMT), including hepatic hemangioma (HH), hepatic epithelioid hemangioendothelioma (HEHE), and hepatic perivascular epithelioid cell tumor (PEComa), and to compare its efficacy with that of [18F]FDG PET/CT. METHODS: A retrospective analysis was conducted on 31 cases of HVAMTs from a prospective parent study (ChiCTR2000039099), including 25 cases of HH (35 lesions), 2 cases of HEHE (18 lesions), and 4 cases of PEComa (6 lesions). All patients underwent both [¹⁸F]FDG and [⁶⁸Ga]Ga-FAPI-04 PET/CT within one week of each other. The detection rates of both imaging modalities in detecting HVAMTs were compared. SUVmax, tumor-to-background ratio (TBR), and correlation between the longest diameter (LD) of lesions and SUVmax were analyzed. The imaging results were validated with pathological evaluations and follow-up examinations. RESULTS: The detection rate for each tumor type by [18F]FDG and [68Ga]Ga-FAPI-04 PET/CT was as follows: HH (2.9% [1/35] vs. 54.3% [19/35], p < 0.001); HEHE (27.8% [5/18] vs. 88.9% [16/18], p = 0.001); PEComa (83.3% [5/6] vs. 100% [6/6]); HVAMT (18.6% [11/59] vs. 69.5% [41/59], p < 0.001). Although [68Ga]Ga-FAPI-04 PET/CT yielded lower median SUVmax than [18F]FDG PET/CT in HH (1.30 vs. 2.30, p < 0.001) and HVAMT (1.60 vs. 2.70, p = 0.001), it exhibited higher TBR than the latter for HH (1.83 vs. 1.07, p < 0.001), HEHE (2.13 vs. 1.19, p < 0.001), PEComa (8.85 vs. 2.28, p = 0.088), and HVAMT (2.25 vs. 1.14, p < 0.001), respectively. In addition, the SUVmax of [68Ga]Ga-FAPI-04 PET/CT showed a significant positive correlation with the LD of lesion in HH (r = 0.777, p < 0.001), HEHE (r = 0.836, p < 0.001), PEComa (r = 0.829, p = 0.042), and HVAMT (r = 0.676, p < 0.001). No such correlation was observed in [18F]FDG PET/CT. CONCLUSION: [68Ga]Ga-FAPI-04 PET/CT was more sensitive than [18F]FDG PET/CT in HVAMTs detection. However, the possibility of lesions being HVMATs should also be evaluated when detecting other common liver tumors using [68Ga]Ga-FAPI-04 PET/CT. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2000039099. Registered 17 October 2020.
引用
- Cheng Z, Zhou J, Kuang D, et al. Performance of [68Ga]Ga-FAPI-04 PET/CT imaging in hepatic vascular-associated mesenchymal tumor: comparison with [18F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2025. PMID: 40702227. doi:10.1007/s00259-025-07446-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。